10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.20549

Form 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 000-53408

MEDICAN ENTERPRISES, INC.

(Exact Name of Registrant as Specified in Its Charter)

Nevada	87-0474017
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

3440 East Russell Road
Las Vegas, NV	89120
(Address of principal executive offices)	(Zip Code)

(800) 416-8802

(Registrant’s telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files).  Yes [X]   No [  ]

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [  ] Accelerated filer [  ] Non-accelerated filer [  ] Smaller reporting company [X]

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

The number of shares of Common Stock, $0.01 par value, outstanding on November 14, 2014 was 50,807,362.

1

MEDICAN ENTERPRISES, INC.

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION
Item 1	Financial Statements	3
	Condensed Consolidated Balance Sheets	3
	Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss	4
	Unaudited Condensed Consolidated Statements of Cash Flows	5
	Notes to the Unaudited Condensed Consolidated Financial Statements	6
Item 2	Management’s Discussion and Analysis or Plan of Operation	12
Item 3	Quantitative and Qualitative Disclosures about Market Risk	14
Item 4	Controls and Procedures	14
PART II – OTHER INFORMATION
Item 1	Legal Proceedings	14
Item 1a	Risk Factors	14
Item 2	Unregistered Sales Of Equity Securities And Use Of Proceeds	15
Item 3	Defaults Upon Senior Securities	15
Item 4	Mine Safety Disclosure	15
Item 5	Other Information	15
Item 6	Exhibits	16
SIGNATURES

2

PART I – FINANCIAL INFORMATION

Item 1. Financial statements.

MEDICAN ENTERPRISES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

SEPTEMBER 30, 2014 AND DECEMBER 31, 2013

(Unaudited)

	September 30, 2014			December 31, 2013
	(Unaudited)			(Audited)
ASSETS
Current asset:
Cash	$	148,818		$	-
Total current assets		148,818			-
Total assets	$	148,818		$	-
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable	$	23,238		$	176,187
Accrued Interest - related parties		4,172			4,172
Convertible Notes Payable (net of discount of $8,750)		232,647			-
Notes Payable - related parties		160,380			116,529
Total current liabilities		420,437			296,888
Convertible Notes Payable (net of discount of $503,500)		502,426			-
Derivative liability		1,212,999			-
Total liabilities		2,135,862			296,888
Stockholders’ Deficit:
Preferred Stock - 5,000,000 shares authorized, $.001 par value; 0 shares issued and outstanding		-			-
Common stock - 100,000,000 shares authorized, $.001 par value; 46,417,475 shares issued and outstanding as of September 30, 2014 and 27,151,240 as of December 31, 2013		46,420			27,151
Additional paid-in capital		46,669,207			770,428
Accumulated deficit		(48,702,671	)		(1,094,467	)
Total  stockholders' deficit		(1,987,044	)		(296,888	)
Total liabilities and stockholders' deficit	$	148,818		$	-

See accompanying notes to unaudited condensed consolidated financial statements.

3

MEDICAN ENTERPRISES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013
(Unaudited)
	Three Months Ended September 30, 2014			Three Months Ended September 30, 2013			Nine Months Ended September 30, 2014			Nine Months Ended September 30, 2013
REVENUE	$	-		$	-		$	-		$	-
OPERATING EXPENSES
Professional Services
Consulting		7,197,286			-			19,393,282			-
Legal		229,158			-			1,444,200			-
Management		15,865			-			14,785,079			-
Investor relations		17			-			8,250,017			-
Stock Compensation		1,334,257			-			3,096,609			-
Selling, General & Administrative		572,914			20,574			797,463			47,659
Total Operating Expenses		9,349,497			20,574			47,766,650			47,659
Loss From Operations		(9,349,497	)		(20,574	)		(47,766,650	)		(47,659	)
OTHER INCOME (EXPENSE):
Related Party Interest Expense		-			(514	)		-			(5,749	)
Gain on revaluation of derivative liability		753,234			-			523,602			-
Loss on excess derivative liability over note principal		(4,967	)		-			(394,998	)		-
NET LOSS	$	(8,601,230	)	$	(21,088	)	$	(47,638,046	)	$	(53,408	)
Currency Translation Adjustment		(5,221	)		-			29,841			-
COMPREHENSIVE LOSS	$	(8,606,451	)	$	(21,088	)	$	(47,608,205	)	$	(53,408	)
NET LOSS PER BASIC AND DILUTED SHARES	$	(0.19	)	$	(0.02	)	$	(1.23	)	$	(0.04	)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING		45,920,813			26,501,240			38,781,267			26,501,240

See accompanying notes to unaudited condensed consolidated financial statements.

4

MEDICAN ENTERPRISES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013
(Unaudited)
	Nine Months Ended September 30, 2014			Nine Months Ended September 30, 2013
Operating Activities:
Comprehensive Loss	$	(47,608,205	)	$	(53,408	)
Adjustments to reconcile net loss to net cash used in operating activities:
Warrants issued as Compensation		2,911,210			-
Stock Compensation Expenses		185,400			-
Loss (gain) on revaluation of derivative liabilities		(523,602	)		-
Loss on excess of derivative liability over note principal		394,998			-
Interest and accretion		602,889			-
Stock Issued for Services:
Consulting		17,338,600			-
Management		14,750,000			-
Legal		1,316,988			-
Investor relations		8,250,000			-
Change in operating assets and liabilities:					-
Accounts payable		(127,950	)
Payables to related parties		-			-
Accrued interest – related party		-			(8,923	)
Net cash used in operating activities:		(2,509,672	)		(62,331	)
Financing Activities:
Notes payable		87,755			-
Convertible Notes		1,515,000			-
Subscription Agreements		1,055,735			-
Proceeds from borrowing, related parties		-			62,331
Net cash provided by financing activities:		2,658,490			62,331
Net change in cash in period		148,818			-
Cash, beginning of period		-			-
Cash, end of period	$	148,818		$	-
Supplemental Disclosure of Cash Flow Information
Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-
Note payable issued for payables to related party	$	-		$	146,309
Related Party debt forgiveness	$	-		$	9,603
Capital stock issued to settle related party debt	$	43,904		$	-

See accompanying notes to unaudited condensed consolidated financial statements.

5

MEDICAN ENTERPRISES, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2014

NOTE 1 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) Organization

Medican Enterprises, Inc., a Nevada corporation (collectively, with its subsidiaries, the “Company”) is a bio-pharmaceutical company focused on pursuing business opportunities in the growing medical and recreational marijuana sector. Through its subsidiaries, the Company is seeking to invest in businesses associated with the growing, marketing, research and development, training, distribution and retail sale of medical and recreational marijuana, both in the United States and Canada.  As of the date of this report, the Company has not commenced the actual the production and sale of medical marijuana but is seeking to lay the foundation to commence this business or related business in the marijuana sector.

The Company was incorporated in Nevada in October, 1988, under the name Extant Investments, Inc. In 1991, the Company merged with and changed its name to Sentinel Scientific, Inc. From 1991 to 1993, the Company was involved with research and development of biomedical technologies, but ceased active operations due to lack of operating capital. In August, 1993, the Company merged with A.F.C. Entertainment, Inc. (“A.F.C.”), a Barbados corporation, which was involved with the foreign film industry. In December, 1993, the Company purchased all of the shares of Film Optical Investments Limited, a corporation organized in the Province of Ontario, Canada (“Film Opticals”) in exchange for 120,000 of its common shares. With the acquisition of Film Opticals, the Company had been engaged in the business of providing a full range of motion picture printing services and creative titles, credits and optical effects for features, commercials, theatrical and television programs. The foreign film library, acquired with the merger of A.F.C., remained intact, but funding constraints curtailed the Company’s ability to develop and market this business. Because of these constraints, the board of directors elected on December 8, 2004, to sell Film Opticals.  On August 6, 2013, the Company changed its name to Medican Enterprises, Inc. to more accurately reflect its current business operation.

The Company currently has four subsidiaries through which it operates.

Medican Systems, Inc. (“Medican Systems”) is a corporation incorporated under the laws of the Territory of the Yukon under incorporation number 535642 on December 30, 2013. The authorized share structure is an unlimited number of common shares without par value, with 100 common shares issued to our company, making Medican Systems our direct wholly-owned subsidiary.  The primary focus of Medican Systems is to function as a holding company for Canadian based investments, joint ventures and opportunities.

Medican (Delta) Systems, Inc. (“Medican Delta”) is a corporation incorporated under the laws of the Province of British Columbia under incorporation number BC0989867 on December 31, 2013 and is a subsidiary of Medican Systems.  The authorized share structure is an unlimited number of common shares without par value, with 100 common shares issued to Medican Systems. The primary focus of Medican Delta is to pursue opportunities in the medical marijuana industry in and around the city of Delta in British Columbia, Canada.

Canaleaf Systems, Inc. (“CanaLeaf”) is a corporation incorporated under laws of Canada under the Canada Business Corporation Act under incorporation number 883348-6 on March 25, 2014 and is also a subsidiary of Medican Systems.  The authorized share structure is an unlimited number of common shares. CanaLeaf is our operating subsidiary focused on business opportunities in Canada.

Medican (US) Systems, Inc. (“Medican US”) is a corporation incorporated under laws of Nevada on September 26, 2014 and is also a subsidiary of Medican Systems.  Medican US is our operating subsidiary focused on business opportunities in the United States.

The unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U. S. generally accepted accounting principles. The unaudited condensed consolidated financial statements of the Company include the accounts of Medican Enterprises, Inc. and its direct and indirect subsidiaries. All significant intercompany transactions have been eliminated. The following summarizes the more significant of such policies:

(b) Statement of Cash Flows

For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.

(c) Income Taxes

The Company applies the provisions of Financial Accounting Standards Board Accounting Standard Codification (“ASC”) 740 Income Taxes.  The Standard requires an asset and liability approach for financial accounting and reporting for income taxes, and the recognition of deferred tax assets and liabilities for the temporary differences between the financial reporting basis and tax basis of the Company’s assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. Due to a loss from inception, the Company has no outstanding tax liability.  At this time the Company has no deferred taxes arising from temporary differences between income for financial reporting and income tax purposes.

6

The Company classifies tax-related penalties and net interest on income taxes as income tax expense. As of June 30, 2014, no income tax expense had been incurred or accrued.

(d)Fair Value Measurements and Financial Instruments

ASC Topic 820 defines fair value, establishes a framework for measuring fair value, establishes a three-level valuation hierarchy for disclosure of fair value measurement and enhances disclosure requirements for fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:

Level 1 - Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 - Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The carrying value of cash, accounts receivable, investment in a related party, accounts payables, accrued expenses, due to related party, notes payable, and convertible notes approximates their fair values due to their short-term maturities.

(e)Foreign currency fluctuations and inflationary pressures may have a negative impact on our financial condition and results of operations.

Our operations in Canada, subject us to foreign currency fluctuations and inflationary pressures which may adversely affect our financial position and results of operations. Since we report our results of operations and financial condition in U.S. dollars, fluctuations in foreign currencies relative to the U.S. dollar may impact our financial results. We do not currently have a hedging program to address foreign currency fluctuations. Any steps taken by us to address foreign currency fluctuations may not eliminate all adverse effects.

(f)  Net Loss per Common Share

Basic loss per common share is based on the weighted-average number of shares outstanding. Diluted income or loss per share is computed using weighted average number of common shares plus dilutive common share equivalents outstanding during the period using the treasury stock method. There are no common stock equivalents outstanding, thus, basic and diluted income or loss per share calculations are the same.  All per share calculations reflect the effects of the forward stock split.

(g) Impairment of Long-Lived Assets

The Company reviews long-lived assets, at least annually, to determine if impairment has occurred and whether the economic benefit of the asset (fair value for assets to be used and fair value less disposal costs for assets to be disposed of) is expected to be less than the carrying value. Triggering events, which signal further analysis, consist of a significant decrease in the asset’s market value, a substantial change in the use of an asset, a significant physical change in the asset, a significant change in the legal or business climate that could affect the asset, an accumulation of costs significantly in excess of the amount originally expected to acquire or construct the asset, or a history of losses that imply continued losses associated with assets used to generate revenue. The Company has no long-lived assets as of June 30, 2014.

(h) Use of Estimates in Preparation of Financial Statements

The preparation of financial statements in conformity with U. S. generally accepted accounting principles (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

(i) Revenue Recognition

The Company shall recognize revenues in accordance with the Securities & Exchange Commission Staff Accounting Bulletin (SAB) number 104, “Revenue Recognition.”  SAB 104 clarifies application of U.S. generally accepted accounting principles to revenue transactions. Accordingly the Company shall recognize revenues when earned which shall be as products or services are delivered to customers. The Company shall also record accounts receivable for revenue earned but not yet collected. An allowance for bad debts shall be provided based on estimated losses. For revenue received in advance of service the Company shall record a current liability as deferred revenue until the earnings process is complete.

7

(j) Impact of New Accounting Standards

The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows.  Based on that review, the Company believes that none of these pronouncements will have a significant effect on its condensed consolidated financial statements.

In June 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders' equity. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. The Company adopted ASU 2014-10 during the quarter ended September 30, 2014, thereby no longer presenting or disclosing any information required by Topic 915.

(k) Derivative financial instruments

The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a weighted average Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

(l) Stock Based Compensation

Shares were issued to various employees as compensation for services rendered. During the nine months ended September 30, 2014, 110,000 common shares were issued at a value of $185,400.

During the nine months ended September 30, 2014, the Company issued 3,230,000 warrants in connection with the share issuances and subscriptions that occurred during the period. The fair value of these warrants was determined to be $6,643,981. All warrants have a term that extends from the date of issuance through June 30, 2015. Accrual of expenses related to these warrants during the nine months ended September 30, 2014 amounted to $2,911,210.   The Company also granted 297,832 warrants in connection with convertible note financing and recorded a derivative liability and corresponding debt discount on the convertible note financing in the amount of $195,927. At September 30, 2014, the fair value of the derivative liability had decreased to $5,445.

NOTE 2 LIQUIDITY/GOING CONCERN

The Company has an accumulated deficit of $48,702,671 as of September 30, 2014, and has had negative cash flows from operating activities during the period from reactivation (January 1, 2005) through September 30, 2014 as well as very limited cash resources as of September 30, 2014.  The loss was primarily due to the issuance of common stock and warrants for professional services.  These factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.  Management plans to continue to seek to build the foundations of its medical and recreational marijuana businesses, but it may be unable to do for a number of reasons, including the inability to reach final agreements with its partners and the inability to raise sufficient funds to commence and operate its business.

NOTE 3 RELATED PARTY TRANSACTIONS AND BALANCES

On March 1, 2014, a $23,330 note payable was issued to a shareholder in return for cash to meet short-term liquidity needs. The note was repaid along with a previous loan balance of $20,574 when the shareholder elected to convert the note into 175,624 shares of the Company’s common stock at a conversion price of $0.275 per share.

On May 8, 2014, the Company issued a 12% convertible note in exchange for cash received of $100,000. The Company must pay 12% interest per annum on the unpaid principal balance, and the principal balance is due on November 8, 2014. Upon the maturity date, the note has a cash redemption premium of 130% of the principal amount. The note may be converted to stock of the Company at a conversion price equal to 45% discount to the average of the three lowest trades on the previous ten trading days to the date of conversion. The Company recognized a derivative liability measured at fair value in the amount of $129,359 in connection with the issuance of this convertible note. At the September 30, 2014, the fair value of the derivative liability had decreased to $99,894.

8

On September 30, 2014, total balances due to related parties amounted to $164,552.  Various loans have been obtained through related parties. These loans constitute the balance of the related party payables as of September 30, 2014. In addition to related party payables, interest is imputed on loans at a 10% non-compounding interest rate.

NOTE 4 EQUITY

On April 23, 2014, the Company filed an Amendment to its Articles of Incorporation with the Nevada Secretary of State increasing its authorized shares to 100,000,000 shares, par value $0.001 per share.

During the nine months ended September 30, 2014, the Company:

i.	Issued 1,667,910 common shares for proceeds of $1,055,735 pursuant to private placements.
ii.	Issued 110,000 common shares valued at $185,290 to officers and employees and recorded stock compensation expense at the market value of shares at the date of issuance.
iii.	Issued 175,624 common shares to a shareholder pursuant to settlement of notes payable of $43,904 due to the shareholder.
iv.	Issued to various consultants 9,553,000 common shares valued at $19,239,046, as payment for consulting services.  Shares were valued as of their respective issuance dates throughout the period.
v.	Issued 559,701 common shares valued at $1,341,428 as payment for legal services. Shares were valued as of their respective issuance dates throughout the period.
vi.	Issued 5,000,000 common shares valued at $14,750,000 as payment for management services. Shares were valued as of their respective issuance dates throughout the period.
vii.	Issued 3,200,000 common shares valued at $8,250,000 as payment for investor relations services. Shares were valued as of their respective issuance dates throughout the period.

During the nine months ended September 30, 2014, the Company issued 3,230,000 warrants issued in connection with the share issuances and subscriptions that occurred during the period. The fair value of these warrants was determined to be $6,643,981. All warrants have a term that extends from the date of issuance through June 30, 2015. Accrual of expenses related to these warrants during the nine months ending September 30, 2014 amounted to $2,911,210.

A summary of the warrants issued as of September 30, 2014 is as follows:

	September 30, 2014
	Number		Weighted Average Exercise Price
Outstanding at December 31, 2013		-	$	-
Issued		5,127,742		0.70
Exercised		-		-
Outstanding and exercisable at September 30, 2014		5,127,742	$	0.70

NOTE 5 CASH AND CASH EQUIVALENT

As of September 30, 2014, total cash balances amounted to $148,818. Of this amount, $42,032 is held in a bank account denominated in Canadian dollars. Because the reporting company reports all balances in US Dollars, transactions over the course of the period which were denominated in Canadian dollars were adjusted as of September 30, 2014 to reflect their value in US Dollars. The effect of this is a foreign currency translation adjustment of $29,841 on the Statement of Operations.

NOTE 6 NOTES PAYABLE

(a)           $115,000 March 31, 2014 Convertible Notes

On March 31, 2014, the Company issued two convertible notes in the principal amounts of $57,500 each. The notes mature on March 31, 2015, are 8% per annum convertible notes and each includes a 5% original issue discount such that the total proceeds to the Company from issuance of the two notes is $115,000 and the purchase price for each note is $55,000.  At the option of the holder after 180 days, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock.  The conversion price for each share is 70% of the average of the 3 lowest closing bid prices for twenty prior trading days.  Interest shall be paid by the Company in common stock.

The Company recorded a derivative liability of $84,506 from the variable conversion pricing of the convertible note and recorded accretion expense of $84,506 relating to the derivative liability from variable conversion pricing during the nine months ended September 30, 2014.  At September 30, 2014, the derivative liability from variable conversion pricing was revalued and the Company recorded a gain on revaluation of $62,601 during the nine months ended September 30, 2014.

9

(b)           $100,000 May 8, 2014 Convertible Note

On May 8, 2014, the Company issued a 12% convertible note in exchange for cash received of $100,000.  The Company must pay 12% interest per annum on the unpaid principal balance, and the principal balance is due on November 8, 2014.  Upon maturity date, the note has a cash redemption premium of 130% of the principal amount.  The note may be converted to stock at a conversion price equal to 45% discount to the average of the three lowest trades on the previous ten trading days to the date of conversion.

The Company recorded a derivative liability of $129,359 from the variable conversion pricing of the convertible note and recorded accretion expense of $101,941 relating to the derivative liability from variable conversion pricing during the nine months ending September 30, 2014. As the amount of derivative liability was in excess of the principal amount of the note, the Company recorded a charge on the statement of operations of $29,359 for the nine months ending September 30, 2014.  At September 30, 2014, the derivative liability from variable conversion pricing was revalued and the Company recorded a gain on revaluation of $29,466 during the nine months ended September 30, 2014.

(c)           $1,105,000 June 4, 2014 Convertible Note

On June 4, 2014, the Company issued a 10% secured convertible promissory note in the principal amount of $1,105,000. The Company must pay 10% interest per annum on the unpaid principal balance which is due November 4, 2015.  The purchase price for the note is $1,000,000, computed as $1,105,000 original principal balance, less the original issue discount (“OID”) of $100,000, less the transaction cost.  On the closing date, the investor shall pay the purchase price to the Company by delivering the following at closing:

a)	The initial cash purchase price of $170,000 and $15,000 of the OID (received)
b)	Secured investor note #1 in the principal amount of $85,000 and $8,500 of the OID
c)	Secured investor note #2 in the principal amount of $85,000 and $8,500 of the OID
d)	Secured investor note #3 in the principal amount of $85,000 and $8,500 of the OID
e)	Secured investor note #4 in the principal amount of $85,000 and $8,500 of the OID
f)	Investor note #5 in the principal amount of $85,000 and $8,500 of the OID
g)	Investor note #6 in the principal amount of $85,000 and $8,500 of the OID
h)	Investor note #7 in the principal amount of $85,000 and $8,500 of the OID
i)	Investor note #8 in the principal amount of $85,000 and $8,500 of the OID
j)	Investor note #9 in the principal amount of $85,000 and $8,500 of the OID
k)	Investor note #10 in the principal amount of $85,000 and $8,500 of the OID

The conversion price for each lender conversion shall be $1.65.  Lender has the right at any time after the purchase price date to convert all or any part of the outstanding balance into shares of common stock. During the nine months ended September 30, 2014, the Company received the first tranche of $170,000 less transaction cost.

As the conversion price at the date of issuance of the note was less than the Company’s market trading price of $2.04 on June 4, 2014, the Company recorded a beneficial conversion feature of $41,212 against additional paid-in capital and recorded accretion expense of $11,435 for the nine months ended September 30, 2014.

(d)           $1,500,000 June 25, 2014 Convertible Note

On June 25, 2014, the Company entered into a Securities Purchase Agreement (the “Agreement”) with a single accredited investor (the “Investor”) in a private placement pursuant to which the Investor purchased a 5% Convertible Note with a face amount of $1,500,000 for a purchase price of $1,000,000  (the “Note”).  The Note bears interest at a rate of 5% per annum and is payable one year after the date of the issuance.  The Company may pay interest due either in cash or, at its option, through freely tradable stock.  The Note will be convertible at the option of the Investor at any time into shares of the Company’s common stock at a conversion price equal to the less of (i) $1.90 and (ii) 70% (60% in the event of default) of the average of the two lowest volume-weighted-average-price of the Common Stock during the 12 consecutive trading days immediately preceding the applicable conversion date.  All or part of the then remaining principal amount of the Note may be prepaid at any time at a price equal to 125% of the sum of the remaining principal amount of the Note to be prepaid plus all accrued and unpaid interest thereon.  The principal amount of the Note will be reduced by $500,000 if the shares of Common Stock underlying the Note are registered for public resale pursuant to an effective registration statement by August 24, 2014.  As at September 30, 2014, the carrying amount of this Convertible Note is $381,535, net of a $500,000 original issuer discount.

In connection with the Agreement, the Investor received a warrant to purchase 297,832 shares of common stock, exercisable for a period of 5 years from the date of issuance at exercise price of $2.15, subject to adjustment.  If a registration statement is not effective for the resale by the Holder of all of the Warrant Shares, the Investor may exercise the warrant on a “cashless” basis. The conversion price of the Note and the exercise price of the Warrant are subject to “full ratchet” anti-dilution adjustment for subsequent lower price issuances by the Company, as well as customary adjustments provisions for stock splits, stock dividends, recapitalizations and the like.  During the nine months ended September 30, 2014, the Company recorded $195,927 as a derivative liability on the issuance of these warrants.  At September 30, 2014, the derivative liability from the issuance of warrants was revalued, resulting in a gain on revaluation of derivative liability of $190,482.  During the nine months ended September 30, 2014, the Company recorded accretion expense of $52,068 on the derivative liability of these warrants.

10

The Company recorded a derivative liability of $1,164,745 from the variable conversion pricing of the convertible note and recorded accretion expense of $309,535 relating to the derivative liability from variable conversion pricing during the nine months ended September 30, 2014.  As the amount of derivative liability was in excess of the principal amount of the note, the Company recorded a charge on the profit and loss of $360,672 for the nine months ending September 30, 2014.  At September 30, 2014, the derivative liability from variable conversion pricing was revalued and the Company recorded a gain on revaluation of $208,714.

(e)           $83,500 September 1, 2014 Convertible Note

On September 1, 2014, the Company issued a convertible note in the principal amount of $83,500. The note matures on June 1, 2015 and bears 8% interest per annum.  At the option of the holder after 180 days, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock.  The conversion price for each share is 58% of the average of the 3 lowest closing bid prices for ten prior trading days.

The Company recorded a derivative liability of $88,467 from the variable conversion pricing of the convertible note and recorded accretion expense of $9,398 relating to the derivative liability from variable conversion pricing during the nine months ended September 30, 2014.  As the amount of derivative liability was in excess of the principal amount of the note, the Company recorded a charge on the profit and loss of $4,967 for the nine months ending September 30, 2014.  At September 30, 2014, the derivative liability from variable conversion pricing was revalued and the Company recorded a gain on revaluation of $12,681 during the nine months ended September 30, 2014.

(f)      $82,688 September 12, 2014 Convertible Note

On September 12, 2014, the Company issued a convertible note in the principal amount of $82,688. The note matures on September 12, 2015 and bears 8% interest per annum.  The note contains a 5% original issue discount such that the purchase price is $78,750. At the option of the holder after 180 days, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock.  The conversion price for each share is 70% of the average of the 3 lowest closing bid prices for twenty prior trading days. Interest shall be payable in common stock.

The Company recorded a derivative liability of $73,597 from the variable conversion pricing of the convertible note and recorded accretion expense of $2,261 relating to the derivative liability from variable conversion pricing during the nine months ended September 30, 2014.  At September 30, 2014, the derivative liability from variable conversion pricing was revalued and the Company recorded a gain on revaluation of $19,660 during the nine months ended September 30, 2014.

NOTE 7 SUBSCRIPTION AGREEMENT

Under the Amendment to the Subscription Agreement that was entered into on April 29, 2014, the Company has agreed to subscribe to up to 50% interest in International Herbs Medical Marijuana Ltd. (“IHMML”), a company that is applying to obtain licensed producer status from Health Canada, according to the following schedule and in the following amounts:

(a)	8,000,000 Shares will be purchased on May 31, 2014 in consideration for payment of CAD$10,000,000 (not paid);
(b)	a further 4,800,000 Shares will be purchased on June 30, 2014 in consideration for payment of CAD$6,000,000 (not paid);
(c)	a further 8,800,000 Shares will be purchased on July 31, 2014 in consideration for payment of CAD$11,000,000 (not paid);
(d)	a further 2,400,000 Shares will be purchased on August 31, 2014 in consideration for payment of CAD$3,000,000 (not paid);
(e)	a further 8,000,000 Shares will be purchased on September 30, 2014 in consideration for payment of CAD$10,000,000 (not paid); and
(f)	October 31, 2014 in consideration for payment of CAD$7,000,000 (not paid).

On July 25, 2014, the Company and CanaLeaf entered into a non-binding letter of intent seeking to amend the Subscription Agreement and restructure its proposed ownership interest in IHMML.  In September 2014, the Company announced that due to structuring and regulatory issues, the prospects for consummating this restructuring are uncertain and that although the Company will continue to monitor this situation, the Company was turning to focus on other potential opportunities.  As such, no assurances can be given that the transactions described in such non-binding letter of intent will be effectuated.

11

NOTE 8 SUBSEQUENT EVENT

On October 21, 2014, the Company entered into a binding letter of intent to acquire Future Harvest Development Ltd. (“Future Harvest”), a Canadian manufacturing company in the home and garden, indoor growing, and hydroponic sector. Under the terms of the letter of intent, the Company will acquire 70% interest in Future Harvest, with an option to acquire the remaining 30%, for approximately $5 million in a combination of cash and common stock.  The acquisition is subject to the preparation and execution of definitive documentation and an audit of Future Harvest.

On October 23, 2014, the back-end note entered into on March 31, 2014, with a face value of $57,500 was funded and the Company received the funds on that date. The Company issued two convertible notes in the principal amounts of $57,500 each. The note matures on March 31, 2015, are 8% per annum convertible notes and each includes a 5% original issue discount such that the total proceeds to the Company from issuance of the note is $55,000 and the purchase price for each note is $55,000.  At the option of the holder after 180 days, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock.  The conversion price for each share is 70% of the average of the 3 lowest closing bid prices for twenty prior trading days.  Interest shall be paid by the Company in common stock.

On November 3, 2014, Adar Bays, LLC elected to convert $5,000 in convertible debt principal and interest into 21,008 shares of common stock with an aggregate fair value of $7,143, valued at $0.34 per share based on the quoted market price of shares at the time of issuance.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Cautionary Note Regarding Forward–Looking Statements

This quarterly report contains forward-looking statements within the meaning of the federal securities laws. These include statements about our expectations, beliefs, intentions or strategies for the future, which we indicate by words or phrases such as "anticipate", "expect", "intend", "plan", "will", “seeking,” "we believe", "the Company believes", "management believes" and similar language. The forward-looking statements are based on the current expectations of the Company and are subject to certain risks, uncertainties and assumptions, including those set forth in the discussion under "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this report. The actual results may differ materially from results anticipated in these forward-looking statements. We base the forward-looking statements on information currently available to us, and we assume no obligation to update them.

Investors are also advised to refer to the information in our filings with the Securities and Exchange Commission, specifically Forms 10-K, 10-Q and 8-K, in which we discuss in more detail various important factors that could cause actual results to differ from expected or historic results. It is not possible to foresee or identify all such factors. As such, investors should not consider any list of such factors to be an exhaustive statement of all risks and uncertainties or potentially inaccurate assumptions.

Except as otherwise indicated by the context, references in this Form 10-Q to “we”, “us”, “our”, “ the Registrant ”, “our Company” or “the Company” refer to Medican Enterprises, Inc., a Nevada corporation. Unless the context otherwise requires, all references to (i) “U.S. dollar”, “$” and “USD” are to United States dollars; (ii) “Canadian dollar” or “CAD” are to Canadian dollars, (iii) “Securities Act” are to the Securities Act of 1933, as amended; and (iv) “Exchange Act” are to the Securities Exchange Act of 1934, as amended.

12

Plan of Operation

We are a bio-pharmaceutical company focused on pursuing business opportunities in the growing medical and recreational marijuana sector. Through our subsidiaries, we are seeking to invest in businesses associated with the growing, marketing, research and development, training, distribution and retail sale of medical and recreational marijuana, both in the United States and Canada.  As of the date of this report, we have not commenced the actual the production and sale of medical marijuana but are seeking to lay the foundation to commence this business or related business in the marijuana sector.

During 2014, we were seeking to acquire a 51% interest in International Herbs Medical Marijuana Ltd. (“IHMML”), a company that is applying to obtain licensed producer status from Health Canada and seeking to establish marijuana growing and distribution facilities in Canada.  On July 25, 2014, we and our CanaLeaf subsidiary entered into a Non-binding Letter of Intent (the “LOI”) with Zenabis Limited Partnership (“Zenabis”) and IHMML.  Pursuant to the LOI, we sought to restructure our proposed acquisition of an interest in IHMML so that we would acquire an outright 51% interest in IHMML and an option to acquire the remainder and, in return, IHMML and its affiliates will obtain a majority ownership interest in and control of our company.  Due to regulatory and structuring challenges, this opportunity is not presently the focus of our operations, but we will continue to monitor IHMML and potentially revisit the opportunity should conditions warrant.

Our plan of operation for the next 12 months is to continue to seek to acquire or establish joint ventures with businesses in the medical and recreational marijuana sector.  To that end, on October 21, 2014, we entered into a binding letter of intent to acquire Future Harvest Development Ltd. (“Future Harvest”), a Canadian manufacturing company in the home and garden, indoor growing, and hydroponic sector. Under the terms of the letter of intent, we will acquire 70% interest in Future Harvest, with an option to acquire the remaining 30%, for approximately $5 million in a combination of cash and common stock.  The acquisition is subject to the preparation and execution of definitive documentation and an audit of Future Harvest.  We are actively seeking similar and other business opportunities in the marijuana sector, including operating businesses such as Future Harvest and the possibility of acquiring real estate which we can then lease to licensed growers in jurisdictions where such activities are permissible.

Based on the current plans and objectives, we will have significant foreseeable cash requirements related to the establishment of our business, including the acquisition of companies and relates costs. Additionally, we will have expenses that related to maintaining our Company’s good standing or the payment of expenses associated with legal fees, accounting fees, outstanding debt and other general operating expenses.  No assurances can be given that we will be able to fund our business or establish our operations, which could cause us to reevaluate our business strategy in its entirety and could lead to the failure of our business.

Critical Accounting Policies and Estimates

Our financial statements and related public financial information are based on the application of accounting principles generally accepted in the United States ("US GAAP"). US GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenues and expenses amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to US GAAP and are consistently and conservatively applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.

Recent Accounting Pronouncements

The Company does not expect that the adoption of any recent accounting pronouncements will have any material impact on its financial statements.

Results of Operations

Three Months Ended September 30, 2014 Compared to Three Months Ended September 30, 2013

Selling, General and Administrative expenses were $572,914 for the September 30, 2014 period, compared to $20,574 for the September 30, 2013 period.  This change in selling, general and administrative expenses for the three months ended September 30, 2014 was primarily due to increased accounting, legal services and compliance fees.  The Company had a net loss of $8,601,230 for the September 30, 2014 period compared to a net loss of $21,088 for the September 30, 2013 period.  The increase in net loss for the three months period ended September 30, 2014 is due to the payments owed under the Subscription Agreement and increased accounting, legal and compliance fees.

We issued 4,781,623 common shares pursuant to consulting, legal, management, and investor relations services, valued at $8,371,742 during the three months ended September 30, 2014, which accounted for the majority of the net loss.  No common shares were issued pursuant to such services in the three months ending September 30, 2013.

13

Nine Months Ended September 30, 2014 Compared to Nine Months Ended September 30, 2013

Selling, General and Administrative expenses were $797,463 for the September 30, 2014 period, compared to $47,659 for the September 30, 2013 period.  This change in selling, general and administrative expenses for the nine months ended September 30, 2014 was primarily due to payments made under the Amended Subscription Agreement associated with our proposed acquisition of IHMML (the “Subscription Agreement”) and increased accounting, legal services and compliance fees.  The Company had a net loss of $47,638,046 for the September 30, 2014 period compared to a net loss of $53,408 for the September 30, 2013 period.  The increase in net loss for the nine month period ended September 30, 2014 is due to the payments owed under the Subscription Agreement and increased accounting, legal and compliance fees.

We issued 18,312,701 common shares pursuant to consulting, legal, management, and investor relations services, valued at $43,590,588 during the nine months ended September 30, 2014, which accounted for the majority of the net loss.  No common shares were issued pursuant to such services in the nine months ending September 30, 2013.

Liquidity and Capital Requirements

On September 30, 2014, we had $148,818 in cash, as compared to no cash or cash equivalents on hand on September 30, 2013. This change is due to the financing activities (such as private placements) we engaged in during such period.

During the nine months ending September 30, 2014, the Company received gross proceeds of $1,055,735 pursuant to private placements (September 30, 2013 - $nil).  The Company received proceeds of $1,515,000 from issuance of various convertible notes (September 30, 2013 - $nil).

Off-Balance Sheet Arrangements

None.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

This item is not applicable as we are currently considered a smaller reporting company.

Item 4. Controls and Procedures.

Our management, with the participation of our principal executive and our principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this quarterly report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by the quarterly report were effective such that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure. A controls system cannot provide absolute assurance, however, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Changes in Internal Control Over Financial Reporting

There have been no changes in internal control over financial reporting.

PART II--OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

Item 1a. Risk Factors.

No material change since the filing of the 10-K on April 15, 2014 for the year ended December 31, 2013.

14

Item 2. Unregistered Sales of Equity Securities And Use Of Proceeds.

Name	Service	Date	Number of Shares Issued	Certificate Number
0845915 B.C. LTD	Consulting	10/30/2014	23,668	854
Barnstorm Communications Corp.	Consulting	10/30/2014	60,146	853
Brunson Chandler & Jones	Legal	10/30/2014	11,905	860
Brunson Chandler & Jones	Legal	10/30/2014	27,028	861
DJ Investment Trust LLC	Consulting	10/30/2014	25,000	862
Kenneth Williams	Director	10/30/2014	10,000	858
Matthew Toren	Consulting	10/30/2014	1,000,000	859
Gary Johnson	Director	10/30/2014	10,000	857
Norman James Payton	Consulting	10/30/2014	1,000,000	855
Michael Thompson	Director	10/30/2014	10,000	856
Vincent Calicchia	Consulting	9/30/2014	7,500	847
National Securities Corporation	Consulting	9/30/2014	17,500	846
Apdel Investments LLC	Consulting	8/18/2014	50,000	839
John Brady	Consulting	8/18/2014	100,000	844
Brunson Chandler & Jones	Legal	8/18/2014	6,623	841
Scout Holdings LLC	Consulting	8/18/2014	100,000	840
Alain Salem	Consulting	7/21/2014	100,000	837
Ralph Olson	Consulting	7/15/2014	300,000	835
Brunson Chandler & Jones, PLLC	Legal	7/7/2014	100,000	833
Green Grow, LLC	Consulting	7/7/2014	4,000,000	832
Kenneth Williams	Employment	7/7/2014	50,000	834
John Brady	Consulting	6/13/2014	1,000,000	829
Brunson Chandler & Jones, PLLC	Legal	6/13/2014	6,411	830
JT Sands Corp.	Consulting	6/13/2014	50,000	828
Anthony Baker	Consulting	5/29/2014	60,000	815
Tyler Bousield	Consulting	5/29/2014	45,110	816
Brunson Chandler & Jones, PLLC	Legal	5/29/2014	6,667	825
Kaycee Buckles	Consulting	5/29/2014	9,000	817
Ken Buckles	Consulting	5/29/2014	20,000	820
Dean Dovanne	Consulting	5/29/2014	10,000	814
Eagle Eye Capital, Inc.	Consulting	5/29/2014	500,000	827
Emerging Growth, LLC	Consulting	5/29/2014	60,000	822
Sandra Jackson	Subscription	5/29/2014	4,500	818
Corey Alvin Lawrence	Subscription	5/29/2014	45,000	819
Dina Lyaskovets	Consulting	5/29/2014	10,000	823
Dina Lyaskovets	Consulting	5/29/2014	10,000	824
Kevin Dale Moore	Subscription	5/29/2014	23,000	813
Andrea Ody	Subscription	5/29/2014	12,500	821
Kenneth Williams	Employment	5/29/2014	20,000	826

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosure.

Not applicable.

Item 5. Other Information.

None.

15

Item 6. Exhibits.

Exhibit Number	Description
31.1	Certification of Chief Executive Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer furnished pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Chief Financial Officer furnished pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MEDICAN ENTERPRISES, INC.
Date: November 14, 2014	By: /S/ Kenneth Williams                                                        Kenneth Williams Chief Executive Officer and Director

Date: November 14, 2014 By: /S/ Wayne Hansen                                                        Kenneth Williams Chief Executive Officer and Director

16

EX-31.1

Exhibit 31.1

SECTION 302 CERTIFICATION

I, Kenneth Williams, certify that: 

1.   I have reviewed this quarterly report on Form 10-Q of Medican Enterprises, Inc.;

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.   Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.   The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a.   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.   Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

c.   Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.   The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a.   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b.   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 14, 2014

/s/ Kenneth Williams

Kenneth Williams

Chief Executive Officer and Director

EX-31.2

Exhibit 31.2

SECTION 302 CERTIFICATION 

I, Wayne Hansen, certify that: 

1.   I have reviewed this quarterly report on Form 10-Q of Medican Enterprises, Inc.;

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.   Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.   The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a.   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.   Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

c.   Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.   The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a.   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b.   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 14, 2014

/s/ Wayne Hansen

Wayne Hansen

Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that this Quarterly Report on Form 10-Q for the quarter ended September 30, 2013 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Medican Enterprises, Inc.

Date: November 14, 2014

/s/ Kenneth Williams

Kenneth Williams

Chief Executive Officer and Director

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 

The undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that this Quarterly Report on Form 10-Q for the quarter ended September 30, 2013 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Medican Enterprises, Inc. 

Date: November 14, 2014

/s/ Wayne Hansen

Wayne Hansen

Chief Financial Officer

XML

Note 8 Subsequent Event (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Oct. 23, 2014
Notes payable	$ 87,755
Subsequent Event
Ownership percent, to be acquired	70.00%
Option to purchase remaining ownership, percent	30.00%
Entity purchase price	5,000,000
Debt Instrument, Face Amount		57,500
Debt Instrument, Maturity Date	Mar. 31, 2015
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Original Issue Discount, Percentage	5.00%
Notes payable	55,000
Debt Instrument, Purchase Price	55,000
Debt Instrument, Convertible, Terms of Conversion Feature	The conversion price for each share is 70% of the average of the 3 lowest closing bid prices for twenty prior trading days.
Debt Conversion, Original Debt, Amount	5,000
Convertible Debt, Fair Value Disclosures	$ 7,143
Subsequent Event | Common Stock
Debt Conversion, Converted Instrument, Shares Issued	21,008
Conversion price for each lender conversion	$ 0.34

XML

Note 4 Equity

9 Months Ended

Sep. 30, 2014

Notes

Note 4 Equity

NOTE 4 EQUITY

 On April 23, 2014, the Company filed an Amendment to its Articles of Incorporation with the Nevada Secretary of State increasing its authorized shares to 100,000,000 shares, par value $0.001 per share.

During the nine months ended September 30, 2014, the Company:

i.	Issued 1,667,910 common shares for proceeds of $1,055,735 pursuant to private placements.
ii.	Issued 110,000 common shares valued at $185,290 to officers and employees and recorded stock compensation expense at the market value of shares at the date of issuance.
iii.	Issued 175,624 common shares to a shareholder pursuant to settlement of notes payable of $43,904 due to the shareholder.
iv.	Issued to various consultants 9,553,000 common shares valued at $19,239,046, as payment for consulting services.  Shares were valued as of their respective issuance dates throughout the period.
v.	Issued 559,701 common shares valued at $1,341,428 as payment for legal services. Shares were valued as of their respective issuance dates throughout the period.
vi.	Issued 5,000,000 common shares valued at $14,750,000 as payment for management services. Shares were valued as of their respective issuance dates throughout the period.
vii.	Issued 3,200,000 common shares valued at $8,250,000 as payment for investor relations services. Shares were valued as of their respective issuance dates throughout the period.

During the nine months ended September 30, 2014, the Company issued 3,230,000 warrants issued in connection with the share issuances and subscriptions that occurred during the period. The fair value of these warrants was determined to be $6,643,981. All warrants have a term that extends from the date of issuance through June 30, 2015. Accrual of expenses related to these warrants during the nine months ending September 30, 2014 amounted to $2,911,210.

A summary of the warrants issued as of September 30, 2014 is as follows:

	September 30, 2014
	Number	Weighted Average Exercise Price
Outstanding at December 31, 2013	-	-
Issued	5,127,742	0.70
Exercised	-	-
Outstanding and exercisable at September 30, 2014	5,127,742	$0.70

XML

Note 3 Related Party Transactions And Balances

9 Months Ended

Sep. 30, 2014

Notes

Note 3 Related Party Transactions And Balances

NOTE 3 RELATED PARTY TRANSACTIONS AND BALANCES

On March 1, 2014, a $23,330 note payable was issued to a shareholder in return for cash to meet short-term liquidity needs. The note was repaid along with a previous loan balance of $20,574 when the shareholder elected to convert the note into 175,624 shares of the Company’s common stock at a conversion price of $0.275 per share.

On May 8, 2014, the Company issued a 12% convertible note in exchange for cash received of $100,000. The Company must pay 12% interest per annum on the unpaid principal balance, and the principal balance is due on November 8, 2014. Upon the maturity date, the note has a cash redemption premium of 130% of the principal amount. The note may be converted to stock of the Company at a conversion price equal to 45% discount to the average of the three lowest trades on the previous ten trading days to the date of conversion. The Company recognized a derivative liability measured at fair value in the amount of $129,359 in connection with the issuance of this convertible note. At the September 30, 2014, the fair value of the derivative liability had decreased to $99,894.

On September 30, 2014, total balances due to related parties amounted to $164,552.  Various loans have been obtained through related parties. These loans constitute the balance of the related party payables as of September 30, 2014. In addition to related party payables, interest is imputed on loans at a 10% non-compounding interest rate.

XML

CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current asset:
Cash	$ 148,818
Total current assets	148,818
Total assets	148,818
Current liabilities:
Accounts payable	23,238	176,187
Accrued Interest - related parties	4,172	4,172
Convertible Notes Payable (net of discount of $8,750)	232,647
Notes Payable - related parties	160,380	116,529
Total current liabilities	420,437	296,888
Convertible Notes Payable (net of discount of $503,500)	502,426
Derivative liability	1,212,999
Total liabilities	2,135,862	296,888
Stockholders' Deficit:
Preferred Stock - 5,000,000 shares authorized, $.001 par value; 0 shares issued and outstanding
Common stock - 100,000,000 shares authorized, $.001 par value; 46,417,475 shares issued and outstanding as of September 30, 2014 and 27,151,240 as of December 31, 2013	46,420	27,151
Additional paid-in capital	46,669,207	770,428
Accumulated deficit	(48,702,671)	(1,094,467)
Total stockholders' deficit	(1,987,044)	(296,888)
Total liabilities and stockholders' deficit	$ 148,818

XML

Note 1 Organization and Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2014

Notes

Note 1 Organization and Summary of Significant Accounting Policies

NOTE 1 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) Organization

Medican Enterprises, Inc., a Nevada corporation (collectively, with its subsidiaries, the “Company”) is a bio-pharmaceutical company focused on pursuing business opportunities in the growing medical and recreational marijuana sector. Through its subsidiaries, the Company is seeking to invest in businesses associated with the growing, marketing, research and development, training, distribution and retail sale of medical and recreational marijuana, both in the United States and Canada.  As of the date of this report, the Company has not commenced the actual the production and sale of medical marijuana but is seeking to lay the foundation to commence this business or related business in the marijuana sector.

The Company was incorporated in Nevada in October, 1988, under the name Extant Investments, Inc. In 1991, the Company merged with and changed its name to Sentinel Scientific, Inc. From 1991 to 1993, the Company was involved with research and development of biomedical technologies, but ceased active operations due to lack of operating capital. In August, 1993, the Company merged with A.F.C. Entertainment, Inc. (“A.F.C.”), a Barbados corporation, which was involved with the foreign film industry. In December, 1993, the Company purchased all of the shares of Film Optical Investments Limited, a corporation organized in the Province of Ontario, Canada (“Film Opticals”) in exchange for 120,000 of its common shares. With the acquisition of Film Opticals, the Company had been engaged in the business of providing a full range of motion picture printing services and creative titles, credits and optical effects for features, commercials, theatrical and television programs. The foreign film library, acquired with the merger of A.F.C., remained intact, but funding constraints curtailed the Company’s ability to develop and market this business. Because of these constraints, the board of directors elected on December 8, 2004, to sell Film Opticals.  On August 6, 2013, the Company changed its name to Medican Enterprises, Inc. to more accurately reflect its current business operation.

The Company currently has four subsidiaries through which it operates.

Medican Systems, Inc. (“Medican Systems”) is a corporation incorporated under the laws of the Territory of the Yukon under incorporation number 535642 on December 30, 2013. The authorized share structure is an unlimited number of common shares without par value, with 100 common shares issued to our company, making Medican Systems our direct wholly-owned subsidiary.  The primary focus of Medican Systems is to function as a holding company for Canadian based investments, joint ventures and opportunities.

Medican (Delta) Systems, Inc. (“Medican Delta”) is a corporation incorporated under the laws of the Province of British Columbia under incorporation number BC0989867 on December 31, 2013 and is a subsidiary of Medican Systems.  The authorized share structure is an unlimited number of common shares without par value, with 100 common shares issued to Medican Systems. The primary focus of Medican Delta is to pursue opportunities in the medical marijuana industry in and around the city of Delta in British Columbia, Canada.

Canaleaf Systems, Inc. (“CanaLeaf”) is a corporation incorporated under laws of Canada under the Canada Business Corporation Act under incorporation number 883348-6 on March 25, 2014 and is also a subsidiary of Medican Systems.  The authorized share structure is an unlimited number of common shares. CanaLeaf is our operating subsidiary focused on business opportunities in Canada.

Medican (US) Systems, Inc. (“Medican US”) is a corporation incorporated under laws of Nevada on September 26, 2014 and is also a subsidiary of Medican Systems.  Medican US is our operating subsidiary focused on business opportunities in the United States.

The unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U. S. generally accepted accounting principles. The unaudited condensed consolidated financial statements of the Company include the accounts of Medican Enterprises, Inc. and its direct and indirect subsidiaries. All significant intercompany transactions have been eliminated. The following summarizes the more significant of such policies:

(b) Statement of Cash Flows

For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.

(c) Income Taxes

The Company applies the provisions of Financial Accounting Standards Board Accounting Standard Codification (“ASC”) 740 Income Taxes.  The Standard requires an asset and liability approach for financial accounting and reporting for income taxes, and the recognition of deferred tax assets and liabilities for the temporary differences between the financial reporting basis and tax basis of the Company’s assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. Due to a loss from inception, the Company has no outstanding tax liability.  At this time the Company has no deferred taxes arising from temporary differences between income for financial reporting and income tax purposes.

The Company classifies tax-related penalties and net interest on income taxes as income tax expense. As of June 30, 2014, no income tax expense had been incurred or accrued.

(d) Fair Value Measurements and Financial Instruments

ASC Topic 820 defines fair value, establishes a framework for measuring fair value, establishes a three-level valuation hierarchy for disclosure of fair value measurement and enhances disclosure requirements for fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:

 Level 1 - Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 Level 2 - Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 The carrying value of cash, accounts receivable, investment in a related party, accounts payables, accrued expenses, due to related party, notes payable, and convertible notes approximates their fair values due to their short-term maturities.

(e) Foreign currency fluctuations and inflationary pressures may have a negative impact on our financial condition and results of operations.

Our operations in Canada, subject us to foreign currency fluctuations and inflationary pressures which may adversely affect our financial position and results of operations. Since we report our results of operations and financial condition in U.S. dollars, fluctuations in foreign currencies relative to the U.S. dollar may impact our financial results. We do not currently have a hedging program to address foreign currency fluctuations. Any steps taken by us to address foreign currency fluctuations may not eliminate all adverse effects.

(f)  Net Loss per Common Share

Basic loss per common share is based on the weighted-average number of shares outstanding. Diluted income or loss per share is computed using weighted average number of common shares plus dilutive common share equivalents outstanding during the period using the treasury stock method. There are no common stock equivalents outstanding, thus, basic and diluted income or loss per share calculations are the same.  All per share calculations reflect the effects of the forward stock split.

(g) Impairment of Long-Lived Assets

The Company reviews long-lived assets, at least annually, to determine if impairment has occurred and whether the economic benefit of the asset (fair value for assets to be used and fair value less disposal costs for assets to be disposed of) is expected to be less than the carrying value. Triggering events, which signal further analysis, consist of a significant decrease in the asset’s market value, a substantial change in the use of an asset, a significant physical change in the asset, a significant change in the legal or business climate that could affect the asset, an accumulation of costs significantly in excess of the amount originally expected to acquire or construct the asset, or a history of losses that imply continued losses associated with assets used to generate revenue. The Company has no long-lived assets as of June 30, 2014.

(h) Use of Estimates in Preparation of Financial Statements

The preparation of financial statements in conformity with U. S. generally accepted accounting principles (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

(i) Revenue Recognition

The Company shall recognize revenues in accordance with the Securities & Exchange Commission Staff Accounting Bulletin (SAB) number 104, “Revenue Recognition.”  SAB 104 clarifies application of U.S. generally accepted accounting principles to revenue transactions. Accordingly the Company shall recognize revenues when earned which shall be as products or services are delivered to customers. The Company shall also record accounts receivable for revenue earned but not yet collected. An allowance for bad debts shall be provided based on estimated losses. For revenue received in advance of service the Company shall record a current liability as deferred revenue until the earnings process is complete.

(j) Impact of New Accounting Standards

The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows.  Based on that review, the Company believes that none of these pronouncements will have a significant effect on its condensed consolidated financial statements.

In June 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders' equity. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. The Company adopted ASU 2014-10 during the quarter ended September 30, 2014, thereby no longer presenting or disclosing any information required by Topic 915.

The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a weighted average Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

(l) Stock Based Compensation

Shares were issued to various employees as compensation for services rendered. During the nine months ended September 30, 2014, 110,000 common shares were issued at a value of $185,400.

During the nine months ended September 30, 2014, the Company issued 3,230,000 warrants in connection with the share issuances and subscriptions that occurred during the period. The fair value of these warrants was determined to be $6,643,981. All warrants have a term that extends from the date of issuance through June 30, 2015. Accrual of expenses related to these warrants during the nine months ended September 30, 2014 amounted to $2,911,210.   The Company also granted 297,832 warrants in connection with convertible note financing and recorded a derivative liability and corresponding debt discount on the convertible note financing in the amount of $195,927. At September 30, 2014, the fair value of the derivative liability had decreased to $5,445.

XML

Note 5 Cash and Cash Equivalent (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Total Cash Balances	$ 148,818
Foreign Currency Transaction Adjustment	(29,841)
Canada, Dollars
Total Cash Balances	$ 42,032

XML

Note 7 Subscription Agreement (Details) (USD $)	9 Months Ended
	Sep. 30, 2014
Voting interest to be purchased	50.00%
May 31, 2014
Common Stock, Shares Subscribed but Unissued	8,000,000
May 31, 2014 | Canada, Dollars
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable	$ 10,000,000
June 30, 2014
Common Stock, Shares Subscribed but Unissued	4,800,000
June 30, 2014 | Canada, Dollars
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable	6,000,000
July 31, 2014
Common Stock, Shares Subscribed but Unissued	8,800,000
July 31, 2014 | Canada, Dollars
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable	11,000,000
August 31, 2014
Common Stock, Shares Subscribed but Unissued	2,400,000
August 31, 2014 | Canada, Dollars
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable	3,000,000
September 30, 2014
Common Stock, Shares Subscribed but Unissued	8,000,000
September 30, 2014 | Canada, Dollars
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable	10,000,000
October 31, 2014 | Canada, Dollars
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable	$ 7,000,000

XML

Note 2 Liquidity/Going Concern

9 Months Ended

Sep. 30, 2014

Notes

Note 2 Liquidity/Going Concern

NOTE 2 LIQUIDITY/GOING CONCERN

The Company has an accumulated deficit of $48,702,671 as of September 30, 2014, and has had negative cash flows from operating activities during the period from reactivation (January 1, 2005) through September 30, 2014 as well as very limited cash resources as of September 30, 2014.  The loss was primarily due to the issuance of common stock and warrants for professional services.  These factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.  Management plans to continue to seek to build the foundations of its medical and recreational marijuana businesses, but it may be unable to do for a number of reasons, including the inability to reach final agreements with its partners and the inability to raise sufficient funds to commence and operate its business.

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Common Stock, par or stated value	$ 0.001	$ 0.001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	46,417,475	27,151,240
Common Stock, shares outstanding	46,417,475	27,151,240
Preferred Stock, par or stated value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Current Portion
Convertible promissory notes discount	$ 8,750	$ 0
Non-Current Portion
Convertible promissory notes discount	$ 503,500	$ 0

XML

Note 1 Organization and Summary of Significant Accounting Policies: (f) Net Loss Per Common Share (Details)	9 Months Ended
	Sep. 30, 2014
Details
Weighted Average Number Diluted Shares Outstanding Adjustment	0

XML

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 14, 2014
Document and Entity Information:
Entity Registrant Name	MEDICAN ENTERPRISES, INC.
Document Type	10-Q
Document Period End Date	Sep. 30, 2014
Amendment Flag	false
Entity Central Index Key	0000847015
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		50,807,362
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3

XML

Note 1 Organization and Summary of Significant Accounting Policies: (l) Stock Based Compensation (Details) (USD $)	9 Months Ended
	Sep. 30, 2014
$1,500,000 June 25, 2014 Convertible Note
Derivative Liability	$ 1,164,745
Common Stock | Various Employees
Stock Issued During Period, Shares, Issued for Services	110,000
Stock Issued During Period, Value, Issued for Services	185,400
Warrant
Allocated Share-based Compensation Expense	2,911,210
Warrant | $1,500,000 June 25, 2014 Convertible Note
Warrants, Issued	297,832
Derivative Liability	195,927
Derivative Liability, Fair Value	5,445
Warrant | Subscriptions
Warrants, Issued	3,230,000
Fair Value of Warrants	$ 6,643,981

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement
REVENUE
OPERATING EXPENSES
Consulting	7,197,286		19,393,282
Legal	229,158		1,444,200
Management	15,865		14,785,079
Investor relations	17		8,250,017
Stock Compensation	1,334,257		3,096,609
Selling, General & Administrative	572,914	20,574	797,463	47,659
Total Operating Expenses	9,349,497	20,574	47,766,650	47,659
Loss From Operations	(9,349,497)	(20,574)	(47,766,650)	(47,659)
OTHER INCOME (EXPENSE):
Related Party Interest Expense		(514)		(5,749)
Gain on revaluation of derivative liability	753,234		523,602
Loss on excess derivative liability over note principal	(4,967)		(394,998)
NET LOSS	(8,601,230)	(21,088)	(47,638,046)	(53,408)
Currency Translation Adjustment	(5,221)		29,841
COMPREHENSIVE LOSS	$ (8,606,451)	$ (21,088)	$ (47,608,205)	$ (53,408)
NET LOSS PER BASIC AND DILUTED SHARES	$ (0.19)	$ (0.02)	$ (1.23)	$ (0.04)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	45,920,813	26,501,240	38,781,267	26,501,240

XML

Note 7 Subscription Agreement

9 Months Ended

Sep. 30, 2014

Notes

Note 7 Subscription Agreement

NOTE 7 SUBSCRIPTION AGREEMENT

Under the Amendment to the Subscription Agreement that was entered into on April 29, 2014, the Company has agreed to subscribe to up to 50% interest in International Herbs Medical Marijuana Ltd. (“IHMML”), a company that is applying to obtain licensed producer status from Health Canada, according to the following schedule and in the following amounts:

(a)	8,000,000 Shares will be purchased on May 31, 2014 in consideration for payment of CAD$10,000,000 (not paid);
(b)	a further 4,800,000 Shares will be purchased on June 30, 2014 in consideration for payment of CAD$6,000,000 (not paid);
(c)	a further 8,800,000 Shares will be purchased on July 31, 2014 in consideration for payment of CAD$11,000,000 (not paid);
(d)	a further 2,400,000 Shares will be purchased on August 31, 2014 in consideration for payment of CAD$3,000,000 (not paid);
(e)	a further 8,000,000 Shares will be purchased on September 30, 2014 in consideration for payment of CAD$10,000,000 (not paid); and
(f)	October 31, 2014 in consideration for payment of CAD$7,000,000 (not paid).

On July 25, 2014, the Company and CanaLeaf entered into a non-binding letter of intent seeking to amend the Subscription Agreement and restructure its proposed ownership interest in IHMML.  In September 2014, the Company announced that due to structuring and regulatory issues, the prospects for consummating this restructuring are uncertain and that although the Company will continue to monitor this situation, the Company was turning to focus on other potential opportunities.  As such, no assurances can be given that the transactions described in such non-binding letter of intent will be effectuated.

XML

Note 6 Notes Payable

9 Months Ended

Sep. 30, 2014

Notes

Note 6 Notes Payable

NOTE 6 NOTES PAYABLE

(a)           $115,000 March 31, 2014 Convertible Notes

On March 31, 2014, the Company issued two convertible notes in the principal amounts of $57,500 each. The notes mature on March 31, 2015, are 8% per annum convertible notes and each includes a 5% original issue discount such that the total proceeds to the Company from issuance of the two notes is $115,000 and the purchase price for each note is $55,000.  At the option of the holder after 180 days, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock.  The conversion price for each share is 70% of the average of the 3 lowest closing bid prices for twenty prior trading days.  Interest shall be paid by the Company in common stock.

The Company recorded a derivative liability of $84,506 from the variable conversion pricing of the convertible note and recorded accretion expense of $84,506 relating to the derivative liability from variable conversion pricing during the nine months ended September 30, 2014.  At September 30, 2014, the derivative liability from variable conversion pricing was revalued and the Company recorded a gain on revaluation of $62,601 during the nine months ended September 30, 2014.

(b)           $100,000 May 8, 2014 Convertible Note

On May 8, 2014, the Company issued a 12% convertible note in exchange for cash received of $100,000.  The Company must pay 12% interest per annum on the unpaid principal balance, and the principal balance is due on November 8, 2014.  Upon maturity date, the note has a cash redemption premium of 130% of the principal amount.  The note may be converted to stock at a conversion price equal to 45% discount to the average of the three lowest trades on the previous ten trading days to the date of conversion.

The Company recorded a derivative liability of $129,359 from the variable conversion pricing of the convertible note and recorded accretion expense of $101,941 relating to the derivative liability from variable conversion pricing during the nine months ending September 30, 2014. As the amount of derivative liability was in excess of the principal amount of the note, the Company recorded a charge on the statement of operations of $29,359 for the nine months ending September 30, 2014.  At September 30, 2014, the derivative liability from variable conversion pricing was revalued and the Company recorded a gain on revaluation of $29,466 during the nine months ended September 30, 2014.

(c)           $1,105,000 June 4, 2014 Convertible Note

On June 4, 2014, the Company issued a 10% secured convertible promissory note in the principal amount of $1,105,000. The Company must pay 10% interest per annum on the unpaid principal balance which is due November 4, 2015.  The purchase price for the note is $1,000,000, computed as $1,105,000 original principal balance, less the original issue discount (“OID”) of $100,000, less the transaction cost.  On the closing date, the investor shall pay the purchase price to the Company by delivering the following at closing:

a)	The initial cash purchase price of $170,000 and $15,000 of the OID (received)
b)	Secured investor note #1 in the principal amount of $85,000 and $8,500 of the OID
c)	Secured investor note #2 in the principal amount of $85,000 and $8,500 of the OID
d)	Secured investor note #3 in the principal amount of $85,000 and $8,500 of the OID
e)	Secured investor note #4 in the principal amount of $85,000 and $8,500 of the OID
f)	Investor note #5 in the principal amount of $85,000 and $8,500 of the OID
g)	Investor note #6 in the principal amount of $85,000 and $8,500 of the OID
h)	Investor note #7 in the principal amount of $85,000 and $8,500 of the OID
i)	Investor note #8 in the principal amount of $85,000 and $8,500 of the OID
j)	Investor note #9 in the principal amount of $85,000 and $8,500 of the OID
k)	Investor note #10 in the principal amount of $85,000 and $8,500 of the OID

The conversion price for each lender conversion shall be $1.65.  Lender has the right at any time after the purchase price date to convert all or any part of the outstanding balance into shares of common stock. During the nine months ended September 30, 2014, the Company received the first tranche of $170,000 less transaction cost.

As the conversion price at the date of issuance of the note was less than the Company’s market trading price of $2.04 on June 4, 2014, the Company recorded a beneficial conversion feature of $41,212 against additional paid-in capital and recorded accretion expense of $11,435 for the nine months ended September 30, 2014.

(d)           $1,500,000 June 25, 2014 Convertible Note

On June 25, 2014, the Company entered into a Securities Purchase Agreement (the “Agreement”) with a single accredited investor (the “Investor”) in a private placement pursuant to which the Investor purchased a 5% Convertible Note with a face amount of $1,500,000 for a purchase price of $1,000,000  (the “Note”).  The Note bears interest at a rate of 5% per annum and is payable one year after the date of the issuance.  The Company may pay interest due either in cash or, at its option, through freely tradable stock.  The Note will be convertible at the option of the Investor at any time into shares of the Company’s common stock at a conversion price equal to the less of (i) $1.90 and (ii) 70% (60% in the event of default) of the average of the two lowest volume-weighted-average-price of the Common Stock during the 12 consecutive trading days immediately preceding the applicable conversion date.  All or part of the then remaining principal amount of the Note may be prepaid at any time at a price equal to 125% of the sum of the remaining principal amount of the Note to be prepaid plus all accrued and unpaid interest thereon.  The principal amount of the Note will be reduced by $500,000 if the shares of Common Stock underlying the Note are registered for public resale pursuant to an effective registration statement by August 24, 2014.  As at September 30, 2014, the carrying amount of this Convertible Note is $381,535, net of a $500,000 original issuer discount.

In connection with the Agreement, the Investor received a warrant to purchase 297,832 shares of common stock, exercisable for a period of 5 years from the date of issuance at exercise price of $2.15, subject to adjustment.  If a registration statement is not effective for the resale by the Holder of all of the Warrant Shares, the Investor may exercise the warrant on a “cashless” basis. The conversion price of the Note and the exercise price of the Warrant are subject to “full ratchet” anti-dilution adjustment for subsequent lower price issuances by the Company, as well as customary adjustments provisions for stock splits, stock dividends, recapitalizations and the like.  During the nine months ended September 30, 2014, the Company recorded $195,927 as a derivative liability on the issuance of these warrants.  At September 30, 2014, the derivative liability from the issuance of warrants was revalued, resulting in a gain on revaluation of derivative liability of $190,482.  During the nine months ended September 30, 2014, the Company recorded accretion expense of $52,068 on the derivative liability of these warrants.

The Company recorded a derivative liability of $1,164,745 from the variable conversion pricing of the convertible note and recorded accretion expense of $309,535 relating to the derivative liability from variable conversion pricing during the nine months ended September 30, 2014.  As the amount of derivative liability was in excess of the principal amount of the note, the Company recorded a charge on the profit and loss of $360,672 for the nine months ending September 30, 2014.  At September 30, 2014, the derivative liability from variable conversion pricing was revalued and the Company recorded a gain on revaluation of $208,714.

(e)           $83,500 September 1, 2014 Convertible Note

On September 1, 2014, the Company issued a convertible note in the principal amount of $83,500. The note matures on June 1, 2015 and bears 8% interest per annum.  At the option of the holder after 180 days, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock.  The conversion price for each share is 58% of the average of the 3 lowest closing bid prices for ten prior trading days.

The Company recorded a derivative liability of $88,467 from the variable conversion pricing of the convertible note and recorded accretion expense of $9,398 relating to the derivative liability from variable conversion pricing during the nine months ended September 30, 2014.  As the amount of derivative liability was in excess of the principal amount of the note, the Company recorded a charge on the profit and loss of $4,967 for the nine months ending September 30, 2014.  At September 30, 2014, the derivative liability from variable conversion pricing was revalued and the Company recorded a gain on revaluation of $12,681 during the nine months ended September 30, 2014.

(f)      $82,688 September 12, 2014 Convertible Note

On September 12, 2014, the Company issued a convertible note in the principal amount of $82,688. The note matures on September 12, 2015 and bears 8% interestper annum.  The note contains a 5% original issue discount such that the purchase price is $78,750. At the option of the holder after 180 days, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock.  The conversion price for each share is 70% of the average of the 3 lowest closing bid prices for twenty prior trading days. Interest shall be payable in common stock.

The Company recorded a derivative liability of $73,597 from the variable conversion pricing of the convertible note and recorded accretion expense of $2,261 relating to the derivative liability from variable conversion pricing during the nine months ended September 30, 2014.  At September 30, 2014, the derivative liability from variable conversion pricing was revalued and the Company recorded a gain on revaluation of $19,660 during the nine months ended September 30, 2014.

XML

Note 6 Notes Payable (Details) (USD $)	3 Months Ended	9 Months Ended		9 Months Ended		9 Months Ended		9 Months Ended													9 Months Ended		9 Months Ended			9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Jun. 04, 2014	Sep. 30, 2014 $115,000 March 31, 2014 Convertible Notes	Mar. 31, 2014 $115,000 March 31, 2014 Convertible Notes	Sep. 30, 2014 $100,000 May 8, 2014 Convertible Note	May 08, 2014 $100,000 May 8, 2014 Convertible Note	Sep. 30, 2014 $1,105,000 June 4, 2014 Convertible Note	Jun. 04, 2014 $1,105,000 June 4, 2014 Convertible Note	Jun. 04, 2014 Initial Cash Purchase Price	Jun. 04, 2014 Secured investor note #1	Jun. 04, 2014 Secured investor note #2	Jun. 04, 2014 Secured investor note #3	Jun. 04, 2014 Secured investor note #4	Jun. 04, 2014 Investor note #5	Jun. 04, 2014 Investor note #6	Jun. 04, 2014 Investor note #7	Jun. 04, 2014 Investor note #8	Jun. 04, 2014 Investor note #9	Jun. 04, 2014 Investor note #10	Sep. 30, 2014 $1,500,000 June 25, 2014 Convertible Note	Jun. 25, 2014 $1,500,000 June 25, 2014 Convertible Note	Sep. 30, 2014 $1,500,000 June 25, 2014 Convertible Note Warrant	Sep. 30, 2014 $83,500 September 1, 2014 Convertible Note	Sep. 01, 2014 $83,500 September 1, 2014 Convertible Note	Sep. 30, 2014 $82,688 September 12, 2014 Convertible Note	Sep. 12, 2014 $82,688 September 12, 2014 Convertible Note
Debt Instrument, Face Amount					$ 115,000		$ 100,000		$ 1,105,000	$ 170,000	$ 85,000	$ 85,000	$ 85,000	$ 85,000	$ 85,000	$ 85,000	$ 85,000	$ 85,000	$ 85,000	$ 85,000		$ 1,500,000			$ 83,500		$ 82,688
Debt Instrument, Maturity Date				Mar. 31, 2015		Nov. 08, 2014		Nov. 04, 2015																Jun. 01, 2015		Sep. 12, 2015
Debt Instrument, Interest Rate, Stated Percentage					8.00%		12.00%		10.00%													5.00%			8.00%		8.00%
Original Issue Discount, Percentage				5.00%
Proceeds from Convertible Notes		1,515,000		115,000				170,000
Debt Instrument, Purchase Price				55,000				1,000,000													1,000,000					78,750
Debt Instrument, Convertible, Terms of Conversion Feature				At the option of the holder after 180 days, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock. The conversion price for each share is 70% of the average of the 3 lowest closing bid prices for twenty prior trading days. Interest shall be paid by the Company in common stock.		The note may be converted to stock at a conversion price equal to 45% discount to the average of the three lowest trades on the previous ten trading days to the date of conversion															The Note will be convertible at the option of the Investor at any time into shares of the Company’s common stock at a conversion price equal to the less of (i) $1.90 and (ii) 70% (60% in the event of default) of the average of the two lowest volume-weighted-average-price of the Common Stock during the 12 consecutive trading days immediately preceding the applicable conversion date
Derivative Liability				84,506		99,894	129,359														1,164,745		195,927	88,467		73,597
Accretion expense		602,889		84,506		101,941		11,435													309,535		52,068	9,398		2,261
Gain (loss) on revaluation of derivative liability	753,234	523,602		62,601		29,466															208,714		190,482	12,681		19,660
Cash Redemption Premium						130.00%
Loss on excess derivative liability over note principal	(4,967)	(394,998)				29,359															360,672			4,967
Original issue discount									100,000	15,000	8,500	8,500	8,500	8,500	8,500	8,500	8,500	8,500	8,500	8,500	500,000
Original issue discount									100,000	15,000	8,500	8,500	8,500	8,500	8,500	8,500	8,500	8,500	8,500	8,500	500,000
Conversion price for each lender conversion									$ 1.65
Market trading price			$ 2.04
Beneficial Conversion Feature								41,212
Debt Instrument, Redemption, Description																					All or part of the then remaining principal amount of the Note may be prepaid at any time at a price equal to 125% of the sum of the remaining principal amount of the Note to be prepaid plus all accrued and unpaid interest thereon.
Debt Instrument, Description																					The principal amount of the Note will be reduced by $500,000 if the shares of Common Stock underlying the Note are registered for public resale pursuant to an effective registration statement by August 24, 2014
Carrying amount																					$ 381,535
Warrants, Issued																							297,832
Exercise Price																							$ 2.15
Debt Conversion, Description																								At the option of the holder after 180 days, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock. The conversion price for each share is 58% of the average of the 3 lowest closing bid prices for ten prior trading days.		The conversion price for each share is 70% of the average of the 3 lowest closing bid prices for twenty prior trading days. Interest shall be payable in common stock

XML

Note 2 Liquidity/Going Concern (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Details
Accumulated deficit	$ (48,702,671)	$ (1,094,467)

XML

Note 1 Organization and Summary of Significant Accounting Policies (Details) (USD $)	1 Months Ended			9 Months Ended
	Dec. 31, 1993	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014 Medican Systems	Sep. 30, 2014 Medican (Delta)	Sep. 30, 2014 Canaleaf Systems	Sep. 30, 2014 Medican (US) Systems, Inc.	Sep. 30, 2014 Film Optical Investments Limited
Common Stock Shares Issued in Exchange for Purchases of shares of Film Opticals	120,000
Entity Information, Date to Change Former Legal or Registered Name								Aug. 06, 2013
Entity Incorporation, Date of Incorporation				Dec. 30, 2013	Dec. 31, 2013	Mar. 25, 2014	Sep. 26, 2014
Common Stock, par or stated value		$ 0.001	$ 0.001	$ 0	$ 0
Subsidiary or Equity Method Investee, Cumulative Number of Shares Issued for All Transactions				100	100

XML

Note 8 Subsequent Event

9 Months Ended

Sep. 30, 2014

Notes

Note 8 Subsequent Event

NOTE 8 SUBSEQUENT EVENT

On October 21, 2014, the Company entered into a binding letter of intent to acquire Future Harvest Development Ltd. (“Future Harvest”), a Canadian manufacturing company in the home and garden, indoor growing, and hydroponic sector. Under the terms of the letter of intent, the Company will acquire 70% interest in Future Harvest, with an option to acquire the remaining 30%, for approximately $5 million in a combination of cash and common stock.  The acquisition is subject to the preparation and execution of definitive documentation and an audit of Future Harvest.

On October 23, 2014, the back-end note entered into on March 31, 2014, with a face value of $57,500 was funded and the Company received the funds on that date. The Company issued two convertible notes in the principal amounts of $57,500 each. The note matures on March 31, 2015, are 8% per annum convertible notes and each includes a 5% original issue discount such that the total proceeds to the Company from issuance of the note is $55,000 and the purchase price for each note is $55,000.  At the option of the holder after 180 days, all or any amount of the principal of the note then outstanding may be converted into shares of the Company’s common stock.  The conversion price for each share is 70% of the average of the 3 lowest closing bid prices for twenty prior trading days.  Interest shall be paid by the Company in common stock.

On November 3, 2014, Adar Bays, LLC elected to convert $5,000 in convertible debt principal and interest into 21,008 shares of common stock with an aggregate fair value of $7,143, valued at $0.34 per share based on the quoted market price of shares at the time of issuance.

XML

Note 1 Organization and Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2014

Policies

(b) Statement of Cash Flows

(b) Statement of Cash Flows

For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.

(c) Income Taxes

(c) Income Taxes

The Company applies the provisions of Financial Accounting Standards Board Accounting Standard Codification (“ASC”) 740 Income Taxes.  The Standard requires an asset and liability approach for financial accounting and reporting for income taxes, and the recognition of deferred tax assets and liabilities for the temporary differences between the financial reporting basis and tax basis of the Company’s assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. Due to a loss from inception, the Company has no outstanding tax liability.  At this time the Company has no deferred taxes arising from temporary differences between income for financial reporting and income tax purposes.

The Company classifies tax-related penalties and net interest on income taxes as income tax expense. As of June 30, 2014, no income tax expense had been incurred or accrued.

(d) Fair Value Measurements and Financial Instruments

(d) Fair Value Measurements and Financial Instruments

ASC Topic 820 defines fair value, establishes a framework for measuring fair value, establishes a three-level valuation hierarchy for disclosure of fair value measurement and enhances disclosure requirements for fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:

 Level 1 - Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 Level 2 - Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 The carrying value of cash, accounts receivable, investment in a related party, accounts payables, accrued expenses, due to related party, notes payable, and convertible notes approximates their fair values due to their short-term maturities.

(e) Foreign Currency

(e) Foreign currency fluctuations and inflationary pressures may have a negative impact on our financial condition and results of operations.

Our operations in Canada, subject us to foreign currency fluctuations and inflationary pressures which may adversely affect our financial position and results of operations. Since we report our results of operations and financial condition in U.S. dollars, fluctuations in foreign currencies relative to the U.S. dollar may impact our financial results. We do not currently have a hedging program to address foreign currency fluctuations. Any steps taken by us to address foreign currency fluctuations may not eliminate all adverse effects.

(f) Net Loss Per Common Share

(f)  Net Loss per Common Share

Basic loss per common share is based on the weighted-average number of shares outstanding. Diluted income or loss per share is computed using weighted average number of common shares plus dilutive common share equivalents outstanding during the period using the treasury stock method. There are no common stock equivalents outstanding, thus, basic and diluted income or loss per share calculations are the same.  All per share calculations reflect the effects of the forward stock split.

(g) Impairment of Long-lived Assets

(g) Impairment of Long-Lived Assets

The Company reviews long-lived assets, at least annually, to determine if impairment has occurred and whether the economic benefit of the asset (fair value for assets to be used and fair value less disposal costs for assets to be disposed of) is expected to be less than the carrying value. Triggering events, which signal further analysis, consist of a significant decrease in the asset’s market value, a substantial change in the use of an asset, a significant physical change in the asset, a significant change in the legal or business climate that could affect the asset, an accumulation of costs significantly in excess of the amount originally expected to acquire or construct the asset, or a history of losses that imply continued losses associated with assets used to generate revenue. The Company has no long-lived assets as of June 30, 2014.

(h) Use of Estimates in Preparation of Financial Statements

(h) Use of Estimates in Preparation of Financial Statements

The preparation of financial statements in conformity with U. S. generally accepted accounting principles (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

(i) Revenue Recognition

(i) Revenue Recognition

The Company shall recognize revenues in accordance with the Securities & Exchange Commission Staff Accounting Bulletin (SAB) number 104, “Revenue Recognition.”  SAB 104 clarifies application of U.S. generally accepted accounting principles to revenue transactions. Accordingly the Company shall recognize revenues when earned which shall be as products or services are delivered to customers. The Company shall also record accounts receivable for revenue earned but not yet collected. An allowance for bad debts shall be provided based on estimated losses. For revenue received in advance of service the Company shall record a current liability as deferred revenue until the earnings process is complete.

(j) Impact of New Accounting Standards

(j) Impact of New Accounting Standards

The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows.  Based on that review, the Company believes that none of these pronouncements will have a significant effect on its condensed consolidated financial statements.

In June 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders' equity. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. The Company adopted ASU 2014-10 during the quarter ended September 30, 2014, thereby no longer presenting or disclosing any information required by Topic 915.

The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a weighted average Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

(l) Stock Based Compensation

(l) Stock Based Compensation

Shares were issued to various employees as compensation for services rendered. During the nine months ended September 30, 2014, 110,000 common shares were issued at a value of $185,400.

During the nine months ended September 30, 2014, the Company issued 3,230,000 warrants in connection with the share issuances and subscriptions that occurred during the period. The fair value of these warrants was determined to be $6,643,981. All warrants have a term that extends from the date of issuance through June 30, 2015. Accrual of expenses related to these warrants during the nine months ended September 30, 2014 amounted to $2,911,210.   The Company also granted 297,832 warrants in connection with convertible note financing and recorded a derivative liability and corresponding debt discount on the convertible note financing in the amount of $195,927. At September 30, 2014, the fair value of the derivative liability had decreased to $5,445.

XML

Note 1 Organization and Summary of Significant Accounting Policies: (c) Income Taxes (Details) (USD $)	9 Months Ended
	Sep. 30, 2014
Details
Income Tax Expense	$ 0

XML

Note 4 Equity (Details) (USD $)			9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014 12% convertible note	Sep. 30, 2014 Common Stock	Sep. 30, 2014 Common Stock Officers and Employees	Sep. 30, 2014 Common Stock Consulting Services	Sep. 30, 2014 Common Stock Legal Services	Sep. 30, 2014 Common Stock Management Services	Sep. 30, 2014 Common Stock Investor Relations Services	Sep. 30, 2014 Warrant	Sep. 30, 2014 Warrant Subscriptions
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, par or stated value	$ 0.001	$ 0.001
Stock issued pursuant to private placements, shares				1,667,910
Stock issued pursuant to private placements, value				$ 1,055,735
Stock Issued During Period, Shares, Issued for Services					110,000	9,553,000	559,701	5,000,000	3,200,000
Stock Issued During Period, Value, Issued for Services					185,290	19,239,046	1,341,428	14,750,000	8,250,000
Stock issued pursuant to settlement of notes payable, shares				175,624
Stock issued pursuant to settlement of notes payable, value				43,904
Warrants, Issued											3,230,000
Fair Value of Warrants											6,643,981
Investment Warrants Expiration Date			Jun. 30, 2015
Allocated Share-based Compensation Expense										$ 2,911,210
Outstanding										0
Issued										5,127,742
Issued, Weighted Average Exercise Price										$ 0.70
Exercised										0
Exercised, Weighted Average Exercise Price										$ 0
Outstanding										5,127,742
Outstanding, Weighted Average Exercise Price										$ 0.70

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Operating Activities:
Comprehensive Loss	$ (47,608,205)	$ (53,408)
Adjustments to reconcile net loss to net cash used in operating activities:
Warrants issued as Compensation	2,911,210
Stock Compensation Expenses	185,400
Loss (gain) on revaluation of derivative liabilities	(523,602)
Loss on excess of derivative liability over note principal	394,998
Interest and accretion	602,889
Stock Issued for Services:
Consulting	17,338,600
Management	14,750,000
Legal	1,316,988
Investor relations	8,250,000
Change in operating assets and liabilities:
Accounts payable	(127,950)
Payables to related parties
Accrued interest - related party		(8,923)
Net cash used in operating activities	(2,509,672)	(62,331)
Financing Activities:
Notes payable	87,755
Convertible Notes	1,515,000
Subscription Agreements	1,055,735
Proceeds from borrowing, related parties		62,331
Net cash provided by financing activities	2,658,490	62,331
Net change in cash in period	148,818
Cash, beginning of period
Cash, end of period	148,818
Supplemental Disclosure of Cash Flow Information
Cash paid for interest
Cash paid for taxes
Note payable issued for payables to related party		146,309
Related Party debt forgiveness		9,603
Capital stock issued to settle related party debt	$ 43,904

XML

Note 5 Cash and Cash Equivalent

9 Months Ended

Sep. 30, 2014

Notes

Note 5 Cash and Cash Equivalent

NOTE 5 CASH AND CASH EQUIVALENT

As of September 30, 2014, total cash balances amounted to $148,818. Of this amount, $42,032 is held in a bank account denominated in Canadian dollars. Because the reporting company reports all balances in US Dollars, transactions over the course of the period which were denominated in Canadian dollars were adjusted as of September 30, 2014 to reflect their value in US Dollars. The effect of this is a foreign currency translation adjustment of $29,841 on the Statement of Operations.

XML

Note 3 Related Party Transactions And Balances (Details) (USD $)		9 Months Ended				9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014 $100,000 May 8, 2014 Convertible Note	May 08, 2014 $100,000 May 8, 2014 Convertible Note	Sep. 30, 2014 Loans	Mar. 01, 2014 Investor 12% convertible note	Sep. 30, 2014 Investor 12% convertible note Common Stock	Mar. 01, 2014 Investor 12% convertible note Common Stock
Debt Instrument, Face Amount			$ 100,000		$ 23,330
Loan balance					20,574
Debt Conversion, Converted Instrument, Shares Issued						175,624
Conversion price							$ 0.275
Debt Instrument, Interest Rate, Stated Percentage			12.00%	10.00%
Maturity Date		Nov. 08, 2014
Cash Redemption Premium		130.00%
Derivative Liability		99,894	129,359
Due to Related Parties	$ 164,552